Loading quotes...

Forecast

The analysts' average price target is €227.78 (+20.60%). The median is €234.34 (+24.07%).

Buy	27
Hold	17
Sell	6

Discussions in the community

There is no discussion about this asset yet.

Start discussion

News Go to news feed

Illumina stock falls about 18% despite profit and margin beat

Illumina reported Q3 revenue of $1.13 billion (below consensus) with a gross margin of 69.4% and adjusted earnings per share of $1.44, both above expectations. The company raised its full-year guidance for revenue and adjusted EPS. Investors still punished the stock sharply because the valuation remains high (P/E around 44) and recent re-ratings prompted profit-taking. » More on deraktionaer.de
Illumina secures long-term high margins through consumables monopoly

Illumina generates recurring, highly profitable revenue from selling gene sequencing instruments and the consumables that are essential to use them. With about 80% market share, the company benefits from economies of scale and high switching costs for customers. The growing use of genome sequencing in clinical care and early detection, especially in cancer therapies, provides sustained demand tailwinds. » More on finanzen.net
Illumina shares surge after turnaround and Moderna success

Illumina has recovered after years of weakness: following the failed GRAIL deal and legal costs, the company is returning to organic growth. Second-quarter revenue rose 6.5% to $1.16 billion, with a markedly stronger North America business. The stock is up about 125% year-to-date and hit a multi‑year high, fueled by prospects of rising demand for sequencing and companion diagnostic solutions for personalized cancer vaccines such as those from Moderna and Merck. Investors have already benefited from strong price gains as Illumina expands its market position in sequencing technology and bioinformatics. » More on deraktionaer.de
Illumina's ascent into the S&P 500 frees up passive buying power

Illumina will be added to the S&P 500 on September 21, 2026, which is expected to create short-term passive buying pressure. Sustained demand in clinical sequencing is driving core growth, supported by sequencing instruments such as NovaSeq and recurring revenue from consumables. The strengthened profile is shifting management's focus toward margin expansion in the core business. » More on finanzen.net
Illumina raises targets after strong Q2 and NovaSeq X success

Illumina significantly beat analysts’ expectations for revenue and earnings in Q2 and materially increased its outlook for 2026. Record growth in diagnostic consumables and demand for the NovaSeq X platform are driving recurring revenue. Institutional investors responded with massive buying pressure at high volume. » More on finanzen.net

Historical dividends Dividends

All dividend metrics All metrics

In 2024, Illumina has already paid €2.90 in dividends. The last payout was in June 2024.

Financials

In the last quarter, Illumina had revenue of €992.29m and net profit of €193.36m

(EUR)	September 2026	YoY
Revenue	992.29m	7.26%
Gross profit	729.5m	16.67%
Net profit	193.36m	50.91%
EBITDA	294.43m	10.48%

Fundamentals

Metric	Value
Market capitalization	€29.02bn
Number of shares	151.2m
52-week high/low	€278.81 - €101.53
Dividends	No
Beta	1.45
P/E ratio	36.15
PEG ratio	1.15
P/B ratio	10.22
P/S ratio	7.09

Company profile

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements, as well as cancer detection testing services. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. The company was incorporated in 1998 and is based in San Diego, California.